Form 4: Artivion Director Receives Equity Grant

Director Daniel J. Bevevino was granted 7,576 shares of Artivion, Inc. common stock as part of an equity incentive plan.

Summary

• Director Daniel J. Bevevino acquired 7,576 shares of Artivion, Inc. (AORT) common stock.
• The transaction occurred on May 18, 2026, at a price of $0 per share as part of a Restricted Stock Award (RSA) grant.
• Following this transaction, the director's total beneficial ownership increased to 157,637 shares.
• The shares are subject to a vesting schedule with a vesting date of May 18, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation.

Positives

• Alignment of director interests with shareholders through increased equity ownership.
• Standard equity compensation practice for board members.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on director equity compensation.

Industry Context

StockSavvy.ai notes that director equity grants are standard corporate governance practices designed to align board member incentives with long-term shareholder value creation in the medical device sector.

Comparison to Industry Standards

• The grant of restricted stock units to directors is consistent with standard compensation packages for publicly traded companies in the healthcare and medical technology industries.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity incentive grant.

Next Steps

• Vesting of the 7,576 shares on May 18, 2027.

Key Dates

Keywords

Artivion, AORT, Form 4, Insider Trading, Equity Incentive Plan, Director Compensation